aTyr Pharma Inc (NASDAQ:LIFE) Short Interest Update

Share on StockTwits

aTyr Pharma Inc (NASDAQ:LIFE) saw a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 121,000 shares, a growth of 7.3% from the August 30th total of 112,800 shares. Based on an average daily volume of 92,900 shares, the days-to-cover ratio is presently 1.3 days. Currently, 3.8% of the shares of the company are short sold.

Several equities research analysts have commented on the stock. Citigroup set a $4.00 price target on shares of aTyr Pharma and gave the company a “hold” rating in a research note on Friday, August 30th. ValuEngine upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd.

Shares of NASDAQ LIFE traded up $0.22 during mid-day trading on Tuesday, reaching $3.25. 1,239 shares of the company traded hands, compared to its average volume of 20,824. aTyr Pharma has a fifty-two week low of $2.76 and a fifty-two week high of $11.48. The company has a debt-to-equity ratio of 0.24, a current ratio of 3.88 and a quick ratio of 3.88. The stock has a fifty day simple moving average of $3.39 and a 200-day simple moving average of $2.14.

aTyr Pharma (NASDAQ:LIFE) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($1.80) EPS for the quarter, beating the Zacks’ consensus estimate of ($2.74) by $0.94. The company had revenue of $0.09 million for the quarter.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wedbush Securities Inc. increased its stake in shares of aTyr Pharma by 158.7% during the second quarter. Wedbush Securities Inc. now owns 67,270 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 41,271 shares during the period. Vanguard Group Inc. increased its stake in shares of aTyr Pharma by 1.9% during the second quarter. Vanguard Group Inc. now owns 1,779,024 shares of the biotechnology company’s stock valued at $652,000 after acquiring an additional 33,702 shares during the period. Finally, Renaissance Technologies LLC increased its stake in shares of aTyr Pharma by 19.8% during the second quarter. Renaissance Technologies LLC now owns 1,845,873 shares of the biotechnology company’s stock valued at $676,000 after acquiring an additional 305,314 shares during the period.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.

Featured Article: Treasury Bonds

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Apple’s  Buy Rating Reiterated at JPMorgan Chase & Co.
Apple’s Buy Rating Reiterated at JPMorgan Chase & Co.
BidaskClub Downgrades HD Supply  to Sell
BidaskClub Downgrades HD Supply to Sell
L Brands  Rating Increased to Hold at Zacks Investment Research
L Brands Rating Increased to Hold at Zacks Investment Research
PolySwarm  Market Cap Hits $3.37 Million
PolySwarm Market Cap Hits $3.37 Million
Omni  Tops 24 Hour Volume of $1,804.00
Omni Tops 24 Hour Volume of $1,804.00
Vectrus  Upgraded to “Hold” at Zacks Investment Research
Vectrus Upgraded to “Hold” at Zacks Investment Research


© 2006-2019 Ticker Report